<DOC>
	<DOCNO>NCT01794403</DOCNO>
	<brief_summary>Accelerated Hypofractionation Radiotherapy prostate cancer 36.25 Gy deliver 5 fraction inferior standard treatment 70.2 Gy give 26 fraction respect two-year failure define positive biopsy two year post treatment completion earlier evidence biochemical clinical failure .</brief_summary>
	<brief_title>Radiation Hypofractionation Via Extended Versus Accelerated Therapy ( HEAT ) For Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>1 . Histologically proven prostate adenocarcinoma . Gleason score 27 ( review reference lab UM ) . Biopsy within one year date enrollment . 2 . Clinical stage ≤ T2 base DRE and/or ≤ T3a base MRI ( do ) ; N0Nx ; M0Mx ( AJCC 7th Edition ) Tstage Nstage determine physical exam available image study ( CT , and/or MRI pelvis ; see section 4.5 ) . For MRI , questionable extracapsular extension permit . To distinguish blood tumor ideal study would acquire T2 , T1 noncontrast T1 dynamic contrast enhance sequence , although require . A small amount extracapsular extension permit , long include clinical target volume ( CTV ) constraint meet . Mstage determine physical exam , CT MRI . Bone scan require unless clinical finding suggest possible osseous metastasis . 3 . ProstateSpecific Antigen ( PSA ) ≤ 15 ng/ml , obtain great 3 month prior enrollment . 4 . Patients belong one follow risk group : Low : Clinical stage* T1T2 ; Gleason ≤ 6 , PSA ≤ 10 &amp; &lt; 50 % biopsy core positive . Intermediate : Clinical stage T2bT2c ; Gleason ≤ 6 , PSA ≤ 10 &amp; &lt; 50 % biopsy core positive . Clinical stage T1T2 ; Gleason ≤ 6 , PSA ≤ 10 &amp; ≥50 % biopsy core positive . Clinical stage T1T2 ; Gleason = 7 , PSA ≤ 10 &amp; &lt; 50 % biopsy core positive T1T2 ; Gleason ≤ 6 &amp; PSA &gt; 10 ≤15 &amp; &lt; 50 % biopsy core positive . MRI stage T3a evidence extraprostatic extension allow . Clinical stage base digital rectal exam ( DRE ) . Seminal vesicle invasion MRI eligible . T1a permit subsequent peripheral zone biopsy show tumor . 5 . Prostate volume : ≤ 80 cc . Determined use : volume = π/6 x length x height x width . Measured CT MRI ≤90 day prior enrollment . 6 . Zubrod performance status 01 . 7 . No prior total prostatectomy cryotherapy prostate . Prior suprapubic prostatectomy , transurethral resection laser ablation permit . 8 . No prior radiotherapy prostate lower pelvis . 9 . No implanted hardware material would prohibit appropriate treatment plan treatment delivery , investigator 's opinion . 10 . No chemotherapy malignancy last 5 year . 11 . No history invasive malignancy ( prostate cancer , nonmetastatic basal squamous skin cancer ) last 5 year . 12 . No 4 month androgen deprivation therapy ( ADT ) prior enrollment . If give , prior enrollment , ADT continue radiation plan deliver completion radiation therapy . 13 . Patient must able gold fiducial marker place prostate ( anticoagulant , must clear primary care physician cardiologist ) , patient already fiducial marker place , must accordance protocol specification ( Section 4.2.2 ) 14 . Ability understand willingness sign write informed consent document . 15 . Willingness fill quality life/psychosocial form . 16 . Age &gt; = 35 = &lt; 85 year . 17 . IPSS ( AUA ) score ≤12 1 . Does diagnosis prostate adenocarcinoma . 2 . Patient clinical T3a evidence T3b disease . 3 . Patient stage N1 M1 disease . 4 . Patients PSA great 15 ng/ml . 5 . Patient meet risk group outline section 3.1.4 . 6 . Prostate volume great 80 cc . 7 . Zubrod performance status 2 great . 8 . Prior total prostatectomy . 9 . Prior radiation therapy prostate lower pelvis . 10 . Implanted hardware limit treatment planning delivery ( determine investigator ) . 11 . Chemotherapy within past 5 year . 12 . Diagnosis invasive malignancy within 5 year ( current prostate cancer nonmetastatic basal squamous skin cancer ) . 13 . The use 4 month androgen deprivation therapy ( ADT ) prior enrollment , plan ADT continue radiation deliver completion radiation therapy . 14 . Inability gold fiducial marker place prostate , fiducial marker already place accordance protocol ( Section 4.2.2 ) 15 . Unwilling inability give inform consent . 16 . Not willing fill quality life/psychosocial questionnaire . 17 . IPSS score &gt; 12 . 18 . Age &lt; 35 &gt; 85 year .</criteria>
	<gender>Male</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>Prostate</keyword>
	<keyword>Radiation Therapy</keyword>
	<keyword>Hypofractionation Radiotherapy</keyword>
	<keyword>Extended Hypofractionation Radiotherapy</keyword>
	<keyword>Accelerated Hypofractionation Radiotherapy</keyword>
	<keyword>AHRT</keyword>
	<keyword>EHRT</keyword>
</DOC>